Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDA

Cipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue, the US Food and Drug Administration has said. The recall affects specific batches distributed in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zEldipu
via IFTTT